Navigation Links
Ophthalmology Pioneer Dr. Jeffrey P. Gilbard Dies
Date:8/13/2009

WOBURN, Mass., Aug.13 /PRNewswire/ -- Dr. Jeffrey P. Gilbard, a pioneer in dry eye disease, died Wednesday, August 12, 2009 at Massachusetts General Hospital in Boston. Doctors say the cause of death was complications related to a bicycle accident. He was 55 years old.

Dr. Gilbard is best known for his pioneering research that led to treatments for dry eye disease, a condition that is caused by a chronic lack of moisture in the eye. He also is considered one of the first ophthalmologists and researchers to understand the correlation between nutrition and the health and wellness of the eye.

Dr. Gilbard founded Advanced Vision Research (AVR) in 1995 to market and distribute TheraTears, a revolutionary over-the-counter eye drop he created to treat dry eye. TheraTears quickly became one of the best selling eye lubricants on the market. His holistic approach to eye care included the use of nutritional supplements to improve the ocular surface and to treat and prevent retinal disease. This research resulted in additional products including TheraTears Nutrition, Macutrition and NutriDox.

With numerous patents and 11 products available in stores worldwide, the company has had record sales for 12 consecutive years. The AVR executive team led by Chief Operating Officer Leigh Reynolds will continue to run the company. Neil D. Donnenfeld, senior vice president of Global Sales and Marketing and Ruth Webb who serves as controller will continue to grow the business and offer new products into the marketplace.

"Our company is grieving the loss of its founder and our close friend, Dr. Jeffrey Gilbard," says Leigh Reynolds. "Over the past 12 years, I have worked closely with Jeff to build AVR. Jeff's vision for AVR to make products to prevent suffering due to dry eye and other eye diseases was very clear. We will continue his mission of improving people's quality of life. This is what Jeff would want us to do and there's no better tribute to him than to continue his work."

Neil Donnenfeld adds: "Jeff was blessed with extraordinary intellect and dedication. He combined the two and made a significant difference in the world. He had no greater satisfaction than to hear that one of AVR's products helped a dry-eye sufferer - and he heard that frequently. His legacy will live on through the relief that dry-eye sufferers receive when they use one of his products. We have lost a giant of a man."

In the summer of 1976, as a medical student, Dr. Gilbard met his first patient with dry-eye and decided something had to be done. What began as a summer research project turned into one of the most productive dry eye research programs in the world. In 1978 he received project grant funding from the National Eye Institute, and to this day he remains the youngest scientist in history to have received such funding. His research program had one goal - to develop an eye drop for dry eyes that really worked.

"Jeff Gilbard was an innovative, gifted ophthalmologist and researcher, who made several important contributions to our profession," said Dr. Edward Holland, director of Cornea Service at the Cincinnati Eye Institute. "He was the first person to understand the importance of tear film osmolarity and his development of hypotonic artificial tears containing bicarbonate and potassium is a landmark event in the treatment of dry eye disease. Dr. Gilbard was on the forefront of the treatment of ocular disease and nutritional supplements. Dr. Gilbard's legacy will be the scientific papers he authored, the revolutionary products he developed to help patients with ocular surface and retinal disease and most notably the people whose lives he'll continue to improve."

Born on February 19, 1954 and raised in Roslyn, New York he was the son of a self-educated New York business entrepreneur Harris Gilbard and Frances Gilbard. He attended Brown University, receiving his Bachelor of Arts degree, Magna Cum Laude in 1975. He received his medical degree in 1979 from the College of Physicians and Surgeons at Columbia University. He was an Intern in Internal Medicine at Stanford University Medical Center and served his Ophthalmology residency at Harvard Medical School in the Massachusetts Eye and Ear Infirmary. He remained at Harvard as a Heed Fellow in Cornea. He was a clinical assistant professor of Ophthalmology at Harvard Medical School and director of the Dry Eye and Ocular Surface Disease Clinic at the New England Eye Center in Boston.

Dr. Jeffrey Gilbard is survived by his beloved wife of 19 years, Liz and his three children, who he adored and nurtured. He also leaves behind his twin brother Dr. Steven M. Gilbard, his older brother Dr. Robert J. Gilbard. A memorial service will take place on Monday at 11:00 am at Temple Shir Tikva, 141 Boston Post Road, Wayland, Massachusetts.


'/>"/>
SOURCE Advanced Vision Research
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Ophthalmic Consultants of Long Island (OCLI), the Largest and One of the Most Prestigious Multi-Specialty Ophthalmology Practices on Long Island, Participates in Mission Cataract USA
2. American Academy of Ophthalmology Honors PBS Master Carpenter Norm Abram for His Commitment to Eye Safety
3. Ophthalmology highlights Jan. 2009
4. Lumenis(R) Introduces Four New Products & Delivery Devices at the 2008 American Academy of Ophthalmology Annual Meeting in Atlanta, Georgia USA
5. Long-Term Results of VisionCares Implantable Telescope for End-Stage Macular Degeneration Published in the American Journal of Ophthalmology
6. Second Annual Eye Ball Fights Juvenile Diabetes, Says Oklahoma Academy of Ophthalmology
7. The Most Ordinary Things Can Cause the Most Extraordinary Eye Injuries, Says the Oklahoma Academy of Ophthalmology
8. September Ophthalmology research highlights
9. Highlights from the August 2008 issue of Ophthalmology
10. Mergent, Inc. Announces Changes to the HealthShares(TM) Ophthalmology Index
11. Paloma Pharmaceuticals Presents at the Association for Research in Vision and Ophthalmology Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... ... June 27, 2016 , ... ... industry today announced its strategic partnership with Connance, a healthcare industry leader ... two companies’ proven, proprietary technology combine to provide health systems, hospitals and ...
(Date:6/26/2016)... ... , ... Quality metrics are proliferating in cancer care, and are derived from ... of the beholder, according to experts who offered insights and commentary in the current ... For the full issue, click here . , For the American Society of ...
(Date:6/26/2016)... ... , ... PawPaws brand pet supplements owned by Whole Health Supply ... health of felines. The formula is all-natural and is made from Chinese herbs that ... Cat Kidney Support Supplement Soft Chews are Astragalus Root Extract and Rehmannia Root ...
(Date:6/25/2016)... ... June 25, 2016 , ... Experts from the ... AcademyHealth’s Annual Research Meeting June 26-28, 2016, at the Hynes Convention Center in ... topics including advance care planning, healthcare costs and patient and family engagement. , ...
(Date:6/25/2016)... ... 2016 , ... "With 30 hand-drawn hand gesture animations, FCPX users can easily ... of Pixel Film Studios. , ProHand Cartoon’s package transforms over 1,300 hand-drawn pictures ... . Simply select a ProHand generator and drag it above media or text in ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... , June 23, 2016 Research and ... Global Market - Forecast to 2022" report to their ... treatment method for the patients with kidney failure, it replaces ... fluid from the patient,s blood and thus the treatment helps ... and chloride in balance. Increasing number of ...
(Date:6/23/2016)... , June 23, 2016 Roche (SIX: ... 510(k) clearance for its Elecsys BRAHMS PCT (procalcitonin) assay ... sepsis or septic shock. With this clearance, Roche is ... a fully integrated solution for sepsis risk assessment and ... with bacterial infection and PCT levels in blood can ...
(Date:6/23/2016)... -- Bracket , a leading clinical trial technology and ... platform, Bracket eCOA (SM) 6.0, at the 52 nd ... 2016 in Philadelphia , Pennsylvania.  A demonstration ... of its kind to fully integrate with RTSM, will be ... is a flexible platform for electronic clinical outcomes assessments that ...
Breaking Medicine Technology: